Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 23, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 23, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/22/17 - 3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure
By a News Reporter-Staff News Editor at Drug Week 3 SBio Inc., a leading Chinese biopharmaceutical company, is pleased to announce that it has entered into a Shareholder Agreement with CPE Funds, pursuant to which a Joint Venture shall be established. On September 1st, the JV entered into an Asset Purchase Agreement with Canada- based biologics m
9/22/17 - 50 Ways to Cut Your Health Care Costs
Even with good insurance from your employer, you're most likely paying a larger share of your medical expenses than in the past $11,600 for the average family in 2017, according to the Milliman Medical Index. The median deductible for in-network care charged by large employers is $1,300 for employee-only coverage and $3,000 for families, accordin
9/22/17 - 65 OM OTC Meds
Office Address: Department of Veterans Affairs; National CMOP; 3450 S. 4th St. Trafficway; Leavenworth KS 66048-5581. Description: Department of Veterans Affairs. DMS Pharmaceutical Group, Inc. $185,169.60.
9/22/17 - A hospital discharged Olathe mom's addicted son with prescriptions for 120 opioid pills. One day later, he was dead. [The Kansas City Star]
Sept. 22 Stephanie Price's last phone conversation with her son burns in her memory. Price's son, Jeromy Bubacz, was about to be discharged from Stormont Vail Health in Topeka after a minor medical procedure. Bubacz, 29, had been fighting prescription drug addiction for years after he was diagnosed with sarcoidosis, a lung condition that cost him
9/22/17 - AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
NORTH CHICAGO, Ill. and NEW YORK, Sept. 22, 2017/ PRNewswire/ AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo in c-Met overexpressing non-small cell lung cancer.
9/22/17 - Abeona Therapeutics Announces Upcoming Conference Participation
NEW YORK and CLEVELAND, Sept. 22, 2017 Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced the Company s senior management team and clinical partners will participate in the following investor and industry conferences
9/22/17 - Acer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
Acer Therapeutics Inc.,, a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, Chief Executive Officer and Founder, will provide a corporate overview at the Cantor Fitzgerald Global Healthc
9/22/17 - Addition to Moberg Pharma's management team
STOCKHOLM, September 22nd 2017, Moberg Pharma AB appoints Torbjrn Wrnheim, Director Pharmaceutical Innovation and Development, as a member of Moberg's Management Team, effective from today. Torbjrn Wrnheim has had this position at Moberg Pharma since 2013.. I look forward to keep working together to continue to progress our development prog
9/22/17 - Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
MISSION VIEJO, CA/ ACCESSWIRE/ September 22, 2017/ Aeolus Pharmaceuticals, Inc., a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today presentation of pharmacometric-based analysis confirming the optimal dosing schedule for AEOL 10150 in the treatment of the pulmonary...
9/22/17 - Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer
By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. announced the departure of the Company's Vice President, Finance& Chief Accounting Officer, Genevieve Lemaire, effective on or before September 30, 2017. About Aeterna Zentaris Inc. Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercial
9/22/17 - Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
Agilent Technologies Inc. today announced its Dako PD-L1 IHC 22 C3 pharmDx assay has an expanded label approved by U.S. Food and Drug Administration, for use as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA , an anti-PD-1 therapy manufactured by Merck& Co., Inc., Kenilworth, N.J., USA. First approved by
9/22/17 - AGREEMENT - Breakthrough in availability of HIV medication
The deal guarantees a maximum price of $75 per person per year for three-in-one pills containing Dolutegravir, Tenofovir and Lamivudine, made by pharmaceutical companies Mylan and Aurobindo under licence from Viiv Healthcare. &The considerable price reductions could yield savings of up to $900 m over the next six years, which means we can initiate.
9/22/17 - Allergan Receives Refusal to File Letter from FDA for Vraylar (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia
Allergan plc today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration regarding its Supplemental New Drug Application for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. Upon its preliminary review, FDA determined that the sNDA for treatment of negative sympto
9/22/17 - Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017 [Sport360]
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that results from a clinical phase I study of the drug candidate ADC-1013 will be presented at the Society for Immunotherapy of Cancer 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National...
9/22/17 - Amerigen believes that it is a first applicant to file an Abbreviated New Drug Application "ANDA" for certain strengths of Namzaric containing a...
By a News Reporter-Staff News Editor at Drug Week Amerigen Pharmaceuticals Limited announced that, based on the August 7th, 2017 update to the U.S. Food& Drug Administration's online databasea, the Company believes that it is a first applicant to file an Abbreviated New Drug Application for Namzaric 7/ 10 b and 21/ 10 c containing a "Paragraph
9/22/17 - An Application for the Trademark "FREESTYLE INSULINX" Has Been Filed by Abbott Laboratories
By a News Reporter-Staff News Editor at Health& Medicine Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "FREESTYLE INSULINX" by Michele H. Bowman, representing Abbott Laboratories. The owner/registrar information for this application is: Michele H. Bowman, Abbot
9/22/17 - Antihistamine Drugs Market by Manufacturers,Types,Regions and Applications Research Report Forecast to 2022
This report, with focus on top players in the global and Japan, studies the Antihistamine Drugs market's development status and future trend in the global and Japan. The major players include Akorn Pharmaceuticals Almirall S.A. Auctus Pharma Limited Bayer SA-NV Kyowa Hakko Kirin Co., Ltd. MEDA Pharma GmbH& Co. KG Merck Sharp& Dohme Limited Nippon B
9/22/17 - Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
Aradigm Corporation today announced that Aradigm management will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 2:00 p.m. ET. Aradigm has completed two Phase 3 clinical trials with Linhaliq?, an investigational proprietary formulation of ciprofloxacin for inhalation, for the treatment of NCFBE and.
9/22/17 - Arbutus Presents HBV Data at Upcoming Scientific Conferences
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.. RNA Interference: A New Tool in the Toolbox for Treatment of HBV by Amy Lee, Senior Director, Research HBV Capsid Assembly Inhibitors by Rene Rijnbrand, Vice Preside
9/22/17 - BD and Euroclone Announce Development and Global Distribution Agreement for Tests to Detect Emerging Sexually Transmitted Pathogens
Release date- 21092017- FRANKLIN LAKES, N.J., and SIZIANO, ITALY- BD, a leading global medical technology company, and Euroclone today announced a development and global distribution agreement for molecular tests to detect emerging sexually-transmitted pathogens. According to the World Health Organization, more than 1 million sexually transmitted..
9/22/17 - Beshear hires Morgan & Morgan, three other law firms to go after pain pill industry [Lexington Herald-Leader]
Sept. 22 FRANKFORT Attorney General Andy Beshear announced Friday that he will partner with four law firms to investigate and potentially sue drug manufacturers, distributors and retailers that contributed to Kentucky's opioid abuse epidemic. Of the four, three are from out of state and one is the Kentucky- based firm of former state Supreme Co
9/22/17 - Biopharmaceutical Logistics Market Is Expected to Reach a Valuation of US $120.7 Billion by the End of 2024
Transparency Market Research Report Added "Biopharmaceutical Logistics Market" to its database.Albany, NY 09/22/2017 Several leading players are actively investing in constructing new logistics facilities in various emerging nations to consolidate their regional presence. The market was valued at US $70.9 bn and is projected to surge to reach
9/22/17 - Biosimilars take center stage at 2017 ACR/ARHP Annual Meeting
By a News Reporter-Staff News Editor at Drug Week ATLANTA- "Biosimilars: To Switch or Not to Switch?" Jonathan Kay, Professor of Medicine at the University of Massachusetts, and Dr. Roy Fleischmann, Clinical Professor at the University of Texas Southwestern Medical Center.
9/22/17 - BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
By a News Reporter-Staff News Editor at Drug Week BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX in the U.S. and Xiapex in Europe, announced that BioSpecifics' President, Tom Wegman, will pre
9/22/17 - Blacksburg firm snags funding Blacksburg biotech snags $10 million investment to push new drug into clinical trials
Landos Biopharma, a new Blacksburg startup, burst out of the gate on Thursday with $10 million in venture funding to begin clinical trials of a potentially breakthrough drug. The company was founded earlier this year by Virginia Tech's Josep Bassaganya-Riera, a researcher with a track record of spinout companies. Landos launched earlier this year a
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement